Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT06220526
Recruiting Not applicable

Comparing Menghini-type Needle and Franseen-type Needle in EBUS-TBNA for Sarcoidosis

NCT06220526 · tracked via the Priya Life Science Canada tracker
Sponsor
University Health Network, Toronto
Phase
Not applicable
Started
2023-08-18
Last updated
2026-05-01

Condition(s) studied

Suspected Sarcoidosis

Investigational drug(s) / intervention(s)

endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)

endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA): Transbronchial biopsy with Menghini-type or Franseen type Needle

Study summary

This randomized pilot clinical trial aims to examine whether sample collection with Franseen-type needles are effective for the diagnosis of sarcoidosis, as defined by improved sample quality for pathological diagnosis compared to the conventional Menghini-type needle.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * -Any adult patient aged 18 years or older with enlarged mediastinal and/or hilar lymph nodes * (≥10 mm short-axis diameter on a CT scan), suspected as having sarcoidosis based on clinical * history, physical exam, and other investigations, and booked for EBUS-TBNA. Exclusion Criteria: * -Patients that are unable to provide informed consent \- Patients with lymphadenopathy strongly suspected to be secondary to other diseases based on * clinical history, physical exam, and/or other investigations (e.g., lung cancer, lymphoma, * infection).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Toronto General Hospital Toronto Ontario Recruiting

More University Health Network, Toronto trials in Canada

Ted Rogers Understanding of Exacerbations in Heart Failure 2: Monitor Recruiting
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE) Recruiting
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant Recruiting
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus Starting soon
CfDNA in Hereditary And High-risk Malignancies 2 Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06220526 on ClinicalTrials.gov ↗ ← All trials in Canada